Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05922761 · ClinicalTrials.gov registry record · Phase 2
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
A Phase 2 study of Lung Diseases and Chronic Graft Versus Host Disease, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 5
- Study locations
NCT05922761 is a Phase 2 study of Lung Diseases and Chronic Graft Versus Host Disease that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 45 participants, below the 738-participant average among 31 other Lung Diseases trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT05922761, a Phase 2 study of Lung Diseases and Chronic Graft Versus Host Disease, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS). The name of the study drugs involved in this study are: * Belumosudil (an immunotherapy) * Fluticasone (an intranasal corticosteroid) * Azithromycin (an antibiotic) * Montelukast (a leukotriene receptor antagonist) * Prednisone (a corticosteroid)
Conditions Studied
Interventions
- DRUG Belumosudil
- DRUG Fluticasone
- DRUG Azithromycin
- DRUG Prednisone
- DRUG Montelukast
Study Locations (5)
Massachusetts
- Dana-Farber Cancer Institute - Boston
- Boston Children's Hospital - Boston
- Brigham and Women's Hospital - Boston
Michigan
- University of Michigan - Ann Arbor
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-05-31 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05922761
The ClinicalTrials.gov registry entry for NCT05922761 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 738-participant average among 31 other Lung Diseases trials with a reported enrollment target (94% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Lung Diseases appearing as the primary indexed condition, and to 5 interventions - of which Belumosudil is the first listed.
NCT05922761 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Michigan, Washington.
Frequently Asked Questions
What is clinical trial NCT05922761 about?
NCT05922761 is a clinical study titled "BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)". The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS). The name of the study d...
What is the current status of trial NCT05922761?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2024-05-31. Estimated completion is 2027-12-31.
What conditions does trial NCT05922761 study?
This clinical trial studies the following conditions: Lung Diseases, Chronic Graft Versus Host Disease, Bronchiolitis Obliterans, Bronchiolitis Obliterans Syndrome.
What interventions are being tested in trial NCT05922761?
The interventions under investigation include: Belumosudil (DRUG), Fluticasone (DRUG), Azithromycin (DRUG), Prednisone (DRUG), Montelukast (DRUG).
Who is sponsoring clinical trial NCT05922761?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05922761 being conducted?
This trial has 5 study locations across Massachusetts, Michigan, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Mosliciguat in PH-ILD
ACTIVE NOT RECRUITING · Phase 2
-
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
COMPLETED · Phase 2
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
American Lung Association (ALA) Lung Health Cohort
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.